Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease

Catheterization and Cardiovascular Interventions

Volumn 73, Issue 1, 2009, Pages 98-104

  Limsuwan, Alisa ^a   Khosithseth, Anan ^a   Wanichkul, Suthep ^a   Khowsathit, Pongsak ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Congenital heart disease; Iloprost; Pulmonary hypertension; Pulmonary vascular resistance; Pulmonary vasoreactivity test

Indexed keywords

ILOPROST;

ADOLESCENT; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEART CATHETERIZATION; HEART SURGERY; HUMAN; LUNG VASCULAR RESISTANCE; MALE; PATIENT ASSESSMENT; PREOPERATIVE EVALUATION; PULMONARY HYPERTENSION; RISK ASSESSMENT; SCHOOL CHILD; SURGICAL RISK; SYSTEMIC VASCULAR RESISTANCE; TREATMENT INDICATION; VASODILATATION;

ADMINISTRATION, INHALATION; ADOLESCENT; AEROSOLS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; FEMALE; HEART CATHETERIZATION; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INFANT; MALE; PULMONARY ARTERY; PULMONARY CIRCULATION; SEVERITY OF ILLNESS INDEX; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 60649089805     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21793     Document Type: Article

References (23)

1. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;18:533-547.
2. Hoffman JI, Rudolph AM, Heymann MA. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation 1981;64:873-877.
3. Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: A morphometric approach to pulmonary vascular disease. Circulation 1978;58: 1107-1122.
4. Blackstone EH, Kirklin JW, Bradley EL, DuShane JW, Appelbaum A. Opitmal age and results in repair of large ventricular septal defects. J Thorac Cardiovasc Surg 1976;72:661-679.
5. Clarkson PM, Frye RL, DuShane JW, Burchell HB, Wood EH, Weidman WH. Prognosis for patients with ventricular septal defect and severe pulmonary vascular obstructive disease. Circulation 1968;38:129-135.
6. Friedli B, Kidd BS, Mustard WT, Keith JD. Ventricular septal defect with increased pulmonary vascular resistance. Late results of surgical closure. Am J Cardiol 1974;33:403-409.
7. Bush A, Busst CM, Haworth SG, Hislop AA, Knight WB, Corrin B, et al. Correlations of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease. Br Heart J 1988;59:480-485.
8. Bush A, Busst C, Knight WB, Shinebourne EA. Modification of pulmonary hypertension secondary to congenital heart disease by prostacyclin therapy. Am Rev Respir Dis 1987;136:767-769.
9. Berner M, Beghetti M, Spahr-Schopfer I, Oberhansli I, Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996; 77:532-535.
10. Day RW, Lynch JM, Shaddy RE, Orsmond GS. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. Am J Cardiol 1995;75:196-198.
11. Roberts JD, Jr., Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993;87:447-453.
12. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993;88:2128-2138.
13. Winberg P, Lundell BP, Gustafsson LE. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease. Br Heart J 1994;71:282-286.
14. Marshall HW, Swan HJ, Burchell HB, Wood EH. Effect of breathing oxygen on pulmonary artery pressure and pulmonary vascular resistance in patients with ventricular septal defect. Circulation 1961;23:241-252.
15. Houde C, Bohn DJ, Freedom RM, Rabinovitch M. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J 1993;70:461-468.
16. Bizzarro M, Gross I. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease. Cochrane Database Syst Rev 2005:CD005055.
17. Carroll CL, Backer CL, Mavroudis C, Cook K, Goodman DM. Inhaled prostacyclin following surgical repair of congenital heart disease - A pilot study. J Card Surg 2005;20:436-439.
18. Chen YF, Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 2000;320:223-232.
19. Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: Vasodilator capacity and cellular mechanisms. Circulation 2001;103:544-548.
20. Selzer A, Sudrann RB. Reliability of the determination of cardiac output in man by means of the Fick principle. Circ Res 1958;6:485-490.
21. Hals J, Hagemo PS, Thaulow E, Sorland SJ. Pulmonary vascular resistance in complete atrioventricular septal defect. A comparison between children with and without Down's syndrome. Acta Paediatr 1993;82:595-598.
22. Haworth SG, Reid L. A morphometric study of regional variation in lung structure in infants with pulmonary hypertension and congenital cardiac defect. A justification of lung biopsy. Br Heart J 1978;40:825-831.
23. Wilson NJ, Seear MD, Taylor GP, LeBlanc JG, Sandor GG. The clinical value and risks of lung biopsy in children with congenital heart disease. J Thorac Cardiovasc Surg 1990;99:460-468.